Press releaseGlobe Newswire
Larimar Therapeutics
LRMR · NASDAQ
$2.44+$0.32 (+15.09%)TodayMarket closed ·
Prev close $2.12
Latest news
- Press releaseGlobe Newswire
Century Therapeutics Appoints Joseph Truitt to Board of Directors
- Press releaseGlobe Newswire
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- NewsVandana Singh
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug
- Press releaseGlobe Newswire
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
- Press releaseGlobe Newswire
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
- Press releaseGlobe Newswire
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
- Press releaseGlobe Newswire
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia
- News
Earnings Scheduled For March 19, 2026
- Press releaseGlobe Newswire
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
- NewsAvi Kapoor
C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Acadia Healthcare Posts Upbeat Q4 Earnings, Joins Circle Internet, Resideo Technologies And Other Big Stocks Moving Higher On Wednesday
- NewsAvi Kapoor
Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views
- NewsHenry Khederian
Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releaseGlobe Newswire
Biotech and Big Tech Drive the Morning Narrative
- NewsAvi Kapoor
Dow Gains Over 100 Points; Home Depot Posts Upbeat Earnings
- Press releaseBusiness Wire
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
- Press releaseGlobe Newswire
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- Press releaseBusiness Wire
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- Press releasePRNewswire
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR
- Press releaseBusiness Wire
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR
- Press releaseBusiness Wire
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- NewsAvi Kapoor
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- NewsVandana Singh
Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study
- News
Market-Moving News for September 29th
- NewsAvi Kapoor
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- NewsAvi Kapoor
Crude Oil Down 1%; Webuy Global Shares Spike Higher
- NewsVandana Singh
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
- NewsAvi Kapoor
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
- NewsAvi Kapoor
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- NewsAvi Kapoor
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.